Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open Label, Phase 2 Trial of Immunotherapy With Sipuleucel-T (Provenge®) as Neoadjuvant Treatment in Men With Localized Prostate Cancer

NCT00715104 is registered in ClinicalTrials.gov with Dendreon as lead sponsor.

NCT NCT00715104
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00715104 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open Label, Phase 2 Trial of Immunotherapy With Sipuleucel-T (Provenge®) as Neoadjuvant Treatment in Men With Localized Prostate Cancer
Lead sponsor
Dendreon
Phase
Phase 2
Overall status
Completed
Start date
July 31, 2008
Completion date
December 31, 2013
Enrollment
42 (actual)
Sites
7

Conditions

As the registry lists them; a condition with its own page is linked.

prostate cancer